Phase I trial demonstrates that CD56+ cell infusion improves outcomes in relapsed refractory acute myeloid leukemia, suggesting a new treatment bridge.
Overall, these trials indicated that the FLAG regimen chemotherapy combined with allogeneic KIR ligand-mismatched CD56⁺ NK/NKT-like cell infusion is safe and may serve as an effective bridge to HSCT in 36.3% of patients with refractory/relapsed non-M3 AML.
No takes yet. Share an insight, caveat, or question.
Ghasabeh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: